One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...

Moderna Inc.’s stock fell 3% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered ...

Sales teams are always looking for ways to improve efficiency, close deals faster, and keep leads engaged. A Sales CRM system plays a vital role in managing customer interactions, tracking leads, and ...

We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the next three years, and reducing costs across our business." Moderna included ...

However, despite these short-term headwinds, the long-term prospects of the company are anchored on its product pipeline which ... From the above analysis, the most evident observation is the ...

Blaize’s innovative product ... analysis is clear and in no way misleading or deceptive. To further protect the integrity of our editorial content, we keep a strict separation between our sales ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company focused on developing and commercializing novel therapies for difficult-to-treat cancers, has demonstrated resilience and growth potential in ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

It is also eyeing £2 billion plus in sales for HIV pre-exposure prophylaxis (PrEP) drug Cabenuva (cabotegravir), hepatitis B virus (HBV) antisense drug GSK3228836, and Zejula (niraparib), the ...

Blaize's innovative product pipeline, built on its full-stack programmable processor architecture suite and software platform for AI processing, has resulted in an increasingly robust and growing ...